KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology · NGM
$10.30
Data: 2026-05-14
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$237M
Total market value of the company
Trailing P/E
5.06
Very cheap relative to earnings
Forward P/E
-2.36
Based on estimated future earnings — lower means cheaper
Rev Growth
-87.3%
Year-over-year revenue change
Profit Margin
35.7%
How much profit the company keeps from each dollar of revenue
ROE
19.9%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$21.20
+106% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 5 analysts covering this stock
About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

https://www.kerostx.com

Country: United States Employees: 78 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
7.1% PASS
Debt must be below 33% of total assets
Cash Ratio
121.1% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
DISTRIBUTION
Smart money appears to be selling into strength — caution
Sharpe Ratio
-0.432
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0664
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.606
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-52.3%
Historical annualised return based on price data
Max Drawdown
-86.4%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
31
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
N/A
52W High
$22.55
54% below the year high
52W Low
$10.32
-0% above the year low
Avg Volume
422,416
Average daily shares traded — higher means easier to buy and sell
Short Ratio
4.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
8.2%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$2.37
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.06
Conservative use of debt — low financial risk
Current Ratio
22.62
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
22.11
Like current ratio but excludes inventory — stricter test
Gross Margin
-283.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-7,051.0%
Profit from core operations before interest and tax
Free Cash Flow
$-35,024,500
Negative — the business is spending more than it generates
Revenue (TTM)
$33M
Total revenue over the last 12 months
Net Income
$-85,145,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
5
Target High
$30.00
Target Median
$21.20
Target Low
$16.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-15 BIENAIME JEAN-JACQUES Director 1,000 $10,580
2026-04-15 BIENAIME JEAN-JACQUES Director 1,000 $11,700
2026-04-02 SEEHRA JASBIR Chief Executive Officer 55,000 $16,500
2026-03-09 BIENAIME JEAN-JACQUES Director 2,000 $22,420
2026-03-09 NEWTON CHARLES W. Director 13,215 —
2026-02-19 SEEHRA JASBIR Chief Executive Officer 7,015 $113,433
2026-02-18 LERNER LORENA RAQUEL PH.D. Officer 3,873 $63,324
2026-02-18 CHO ESTHER General Counsel 4,745 $77,581
2026-02-18 REGNANTE KEITH C Chief Financial Officer 4,739 $77,483
2025-10-15 ADAR1 CAPITAL MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security 5,389,264 $95,659,436
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.